2.  In this article was referenced: 

 http://www.clinicaltrials.gov/

 This is a U.S. Gov't agency that does medical testing. 

 

 

3.  I decided to look up H1N1 in the above clinical trials gov web.  If you go into their web link, click the first choice, next page type in H1N1, it will give you test results.

 

 

4.  I looked up the gov'ts research tests by random.  Two that I looked up were #38 and #39:  

 

38	Recruiting	Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study Condition: Influenza Interventions: Drug: oseltamivir;   Other: blank;   Drug: chinese medicinal herbs;   Drug: oseltamivir and chinese medicinal herbs
39	Not yet recruiting	Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Condition: Influenza Interventions: Drug: oseltamivir;   Drug: oseltamivir and chinese medicinal herbs

--------------------------------------------------------------------------------------------------------------------------

 

5.  If you look at #38 below, I have yellowed the part to be seen.  It states WHO verifies that oseltamivir cures H1N1 as their choice of cure but also shows this testing of Chinese Medicinal Herbs cures H1N1.  They do not state what is in the herbs.   This test date started July 2009 and to be completed 2010, but appears already results are positive for Herbs also as cure.  See #38 below : 

 

 

 

Home Search Study Topics Glossary

Study 38 of 69 for search of:

h1n1

Previous Study

Return to Search Results

Next Study

Full Text View

Tabular View

No Study Results Posted

Related Studies

Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study

This study is currently recruiting participants.

Verified by Capital Medical University, September 2009

First Received: July 7, 2009   Last Updated: September 10, 2009   History of Changes

Sponsored by:	Capital Medical University
Information provided by:	Capital Medical University
ClinicalTrials.gov Identifier:	NCT00935194

  Purpose

The purpose of this study is to determine whether Chinese medicinal herbs are effective and safe for treating novel influenza A (H1N1) infection.

Condition	Intervention	Phase
Influenza	Drug: oseltamivir Other: blank Drug: chinese medicinal herbs Drug: oseltamivir and chinese medicinal herbs	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study

Resource links provided by NLM:

MedlinePlus related topics: Fever Flu Marijuana

Drug Information available for: Oseltamivir Tamiflu

U.S. FDA Resources

Further study details as provided by Capital Medical University:

Primary Outcome Measures:

• time to resolution of fever (the period from start of study-drug to relief of fever) [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

• time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms) [ Time Frame: one year ] [ Designated as safety issue: No ]
• virus shedding time [ Time Frame: one year ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	July 2009
Estimated Study Completion Date:	July 2010
Estimated Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
blank: Experimental do not take antiviral therapy	Other: blank no antiviral therapy
Oseltamivir: Experimental antiviral therapy	Drug: oseltamivir 75mg,bid,for 5 days
chinese medicinary herbs: Experimental antiviral therapy	Drug: chinese medicinal herbs 200ml,p.o,qid,for 5 days
oseltalmivir and chinese medicinal herbs: Experimental combination antiviral therapy	Drug: oseltamivir and chinese medicinal herbs oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days

Detailed Description:

The antiviral agent, oseltamivir, is recommended by the World Health Organization (WHO) to treat recent outbreak novel influenza A (H1N1) virus infection around world. But limited stock and resistant strain emergence raised increasing concerns. Chinese medicinal herbs, are derived from plants and usually incorporate one or more herbs as the basic drug(s) to treat the disease. The investigators performed RCT to indicate that Chinese medicinal herbs was effective and safe for treating novel influenza A (H1N1) infection.

  Eligibility

Ages Eligible for Study:	14 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Confirmed novel influenza A(H1N1) case with laboratory evidence
• 70 years ≥ age ≥ 14years
• Within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one respiratory symptom (cough, sore throat, or nasal symptom)

Exclusion Criteria:

• Age < 14 years or > 70 years
• Bronchitis, pneumonia, pleural fluid and interstitial infiltration showed by Chest radiology(x-ray or CT)
• Severe chronic underlying diseases: severe COPD(FEV1/EVC <70% and FEV1 <30% predicted or respiratory failure or congestive heart failure), severe hepatic disfunction（ALT or AST ≥3 times normal elevation), renal disfunction（Cr>2mg/dL), chronic heart failure(NYHA â…¢-â…£ grade）
• Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment with immunosuppressive drug and glucocorticoids in the past 3 months)
• Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks
• Inoculation influenza vaccination

• One of the following items appeared at the enrollment

• respiratory failure：PaO2<60mmHg and/or PCO2>50mmHg or PaO2/FiO2≤300
• circulation failure: despite adequate fluid resuscitation and cardiac output, systolic <90mmHg or requirement inotropic support
• renal function failure: despite adequate fluid resuscitation and cardiac output, urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation
• hepatic function failure: total bilirubin>34μmol/L or ALT/AST ≥3 times normal - Other unappropriated enrollment situations considered by investigator

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00935194

Contacts

Contact: Bin Cao, Doctor	86-010-85231999	caobin1999@gmail.com
Contact: Li Gu, Doctor	86-010-85231130	guliangel@yahoo.com.cn

Locations

China
Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute	Recruiting
Beijing, China, 100020
Contact: Bin Cao, Doctor     86-010-85231167     caobin1999@gmail.com
Principal Investigator: Bin cao, doctor

Sponsors and Collaborators

Capital Medical University

Investigators

Study Chair:	Chen Wang, Doctor	Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute
Principal Investigator:	Qingquan Liu, Docter	Beijing Chinese Traditional Medicine University affiliated Dongzhimen Hospital
Principal Investigator:	Yu Mao, Doctor	Beijing Ditan Hospital

  More Information

No publications provided

Responsible Party:	Capital Medical University Affiliated Beijing Chaoyang Hospital ( Wang Chen )
Study ID Numbers:	Z09000700090903
Study First Received:	July 7, 2009
Last Updated:	September 10, 2009
ClinicalTrials.gov Identifier:	NCT00935194     History of Changes
Health Authority:	China: State Food and Drug Administration

Keywords provided by Capital Medical University:

Novel Influenza A(H1N1) Oseltamivir Chinese Medicinal Herbs

Additional relevant MeSH terms:

Anti-Infective Agents RNA Virus Infections Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Orthomyxoviridae Infections Antiviral Agents Pharmacologic Actions

Oseltamivir Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases Therapeutic Uses Influenza, Human

ClinicalTrials.gov processed this record on October 02, 2009

Home Search Study Topics Glossary

Study 39 of 69 for search of:

h1n1

Previous Study

Return to Search Results

Next Study

Full Text View

Tabular View

No Study Results Posted

Related Studies

Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study

This study is not yet open for participant recruitment.

Verified by Capital Medical University, July 2009

First Received: July 8, 2009   Last Updated: July 14, 2009   History of Changes

Sponsored by:	Capital Medical University
Information provided by:	Capital Medical University
ClinicalTrials.gov Identifier:	NCT00936013

  Purpose

The purpose of the study is to determine whether the combination treatment of Chinese medicinal herbs and oseltamivir is more effective than single oseltamivir in treating novel influenza A (H1N1) pneumonia.

  Eligibility

Ages Eligible for Study:	14 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1.Confirmed novel influenza A(H1N1) case with laboratory evidence 2.70ys≥age≥14ys 3.within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one respiratory symptom (cough, sore throat, or nasal symptom) 4.New lung infiltration showed by chest radiology(x-ray or CT)

Exclusion Criteria:

1. Age<14ys or >70ys
2. Pregnancy
3. Severe chronic underlying diseases: severe COPD(FEV1/EVC <70% and FEV1 <30% predicted or respiratory failure or congestive heart failure), severe liver disfunction（ALT or AST ≥3 times normal elevation), renal disfunction（Cr>2mg/dL), chronic heart failure(NYHA â…¢-â…£ grade）
4. Immunocompromised patients(cancer, organ transplant, AIDS and a history of treatment with immunosuppressive drug and glucocorticoids in the past 3 months)
5. Taken Chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks
6. Inoculation influenza vaccination
7. One of the following items appeared at the enrollment (1)respiratory failure：PaO2<60mmHg and/or PCO2>50mmHg or PaO2/FiO2≤300 (2)circulation failure: despite adequate fluid resuscitation and cardiac output, systolic <90mmHg or requirement inotropic support (3)renal function failure: despite adequate fluid resuscitation and cardiac output, urine ≤ 0.5ml/kg.h, Cr or BUN≥1 time normal elevation (4)liver function failure: total bilirubin>34μmol/L or ALT/AST ≥3 times normal elevation
8. Other unappropriated enrollment situations considered by investigator

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00936013

Contacts

Contact: Bin Cao, Doctor	86-010-85231999	caobin1999@gmail.com
Contact: Li Gu, Doctor	86-85231133	guliangel@yahoo.com.cn

Locations

China

Capital Medical University affiliated Bejing Chaoyang Hospital, Beijing Respiratory Medicine Institute

Beijing, China, 100020

Sponsors and Collaborators

Capital Medical University

Investigators

Study Chair:	Chen Wang, Doctor	Beijing Chaoyang Hospital
Study Director:	Qingquan Liu, Docter	Beijing Chinese Traditional Medicine University affiliated Dongzhimen Hospital
Study Director:	Yu Mao, Doctor	Beijing Ditan Hospital

  More Information

No publications provided

Responsible Party:	Capital Medical University affiliated Beijing Chaoyang Hospital ( Wang Chen )
Study ID Numbers:	Z09000700090903�2
Study First Received:	July 8, 2009
Last Updated:	July 14, 2009
ClinicalTrials.gov Identifier:	NCT00936013     History of Changes
Health Authority:	China: State Food and Drug Administration

Keywords provided by Capital Medical University:

novel influenza A(H1N1); chinese medicinal herbs

Additional relevant MeSH terms:

Anti-Infective Agents RNA Virus Infections Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Orthomyxoviridae Infections Antiviral Agents Pharmacologic Actions

Oseltamivir Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases Therapeutic Uses Influenza, Human

ClinicalTrials.gov processed this record on October 02, 2009